Subcutaneous implantable cardioverter defibrillator: Where do we stand?
The indications for implantable cardioverter defibrillators (ICDs) for the prevention of sudden cardiac death (SCD) have rapidly expanded over the past 15 years. Clinical trial data have quickly been implemented into guidelines. The recently introduced subcutaneous implantable cardioverter defibrill...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Heart India |
| Subjects: | |
| Online Access: | http://www.heartindia.net/article.asp?issn=2321-449x;year=2016;volume=4;issue=2;spage=50;epage=55;aulast=Pande |
| _version_ | 1828923169053868032 |
|---|---|
| author | Arindam Pande Soumya Patra Debabrata Bera Prakas Chandra Mondal Rabin Chakraborty |
| author_facet | Arindam Pande Soumya Patra Debabrata Bera Prakas Chandra Mondal Rabin Chakraborty |
| author_sort | Arindam Pande |
| collection | DOAJ |
| description | The indications for implantable cardioverter defibrillators (ICDs) for the prevention of sudden cardiac death (SCD) have rapidly expanded over the past 15 years. Clinical trial data have quickly been implemented into guidelines. The recently introduced subcutaneous implantable cardioverter defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. The device is now commercially available in India. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation (VF) and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, major disadvantages of this device include inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia. As seen with other early examples of evolutionary technology, we hope improvements in design and manufacture will improve some of the drawbacks of the current generation device. |
| first_indexed | 2024-12-13T22:34:21Z |
| format | Article |
| id | doaj.art-9349d24f814a4383b3ceb351253f993a |
| institution | Directory Open Access Journal |
| issn | 2321-449X |
| language | English |
| last_indexed | 2024-12-13T22:34:21Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Heart India |
| spelling | doaj.art-9349d24f814a4383b3ceb351253f993a2022-12-21T23:29:00ZengWolters Kluwer Medknow PublicationsHeart India2321-449X2016-01-0142505510.4103/2321-449X.183519Subcutaneous implantable cardioverter defibrillator: Where do we stand?Arindam PandeSoumya PatraDebabrata BeraPrakas Chandra MondalRabin ChakrabortyThe indications for implantable cardioverter defibrillators (ICDs) for the prevention of sudden cardiac death (SCD) have rapidly expanded over the past 15 years. Clinical trial data have quickly been implemented into guidelines. The recently introduced subcutaneous implantable cardioverter defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. The device is now commercially available in India. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation (VF) and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, major disadvantages of this device include inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia. As seen with other early examples of evolutionary technology, we hope improvements in design and manufacture will improve some of the drawbacks of the current generation device.http://www.heartindia.net/article.asp?issn=2321-449x;year=2016;volume=4;issue=2;spage=50;epage=55;aulast=PandeImplantable cardioverter defibrillatorsubcutaneoussudden cardiac death |
| spellingShingle | Arindam Pande Soumya Patra Debabrata Bera Prakas Chandra Mondal Rabin Chakraborty Subcutaneous implantable cardioverter defibrillator: Where do we stand? Heart India Implantable cardioverter defibrillator subcutaneous sudden cardiac death |
| title | Subcutaneous implantable cardioverter defibrillator: Where do we stand? |
| title_full | Subcutaneous implantable cardioverter defibrillator: Where do we stand? |
| title_fullStr | Subcutaneous implantable cardioverter defibrillator: Where do we stand? |
| title_full_unstemmed | Subcutaneous implantable cardioverter defibrillator: Where do we stand? |
| title_short | Subcutaneous implantable cardioverter defibrillator: Where do we stand? |
| title_sort | subcutaneous implantable cardioverter defibrillator where do we stand |
| topic | Implantable cardioverter defibrillator subcutaneous sudden cardiac death |
| url | http://www.heartindia.net/article.asp?issn=2321-449x;year=2016;volume=4;issue=2;spage=50;epage=55;aulast=Pande |
| work_keys_str_mv | AT arindampande subcutaneousimplantablecardioverterdefibrillatorwheredowestand AT soumyapatra subcutaneousimplantablecardioverterdefibrillatorwheredowestand AT debabratabera subcutaneousimplantablecardioverterdefibrillatorwheredowestand AT prakaschandramondal subcutaneousimplantablecardioverterdefibrillatorwheredowestand AT rabinchakraborty subcutaneousimplantablecardioverterdefibrillatorwheredowestand |